Sign In
Buy CTLT
$63.49
+0 (+0%)
At Close: Mar 14, 2025
Catalent's (CTLT) Latest Partnership to Boost Clinical Trials
12:21pm, Monday, 13'th May 2024
Catalent's (CTLT) new tie-up to support the development and commercial manufacturing of safe, high-quality AAV gene therapies to provide life-saving treatments to cancer patients.
Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up
02:35pm, Thursday, 09'th May 2024
Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.
Catalent (CTLT) Reports Q3 Loss, Misses Revenue Estimates
08:31pm, Wednesday, 08'th May 2024
Catalent (CTLT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.24. This compares to loss of $0.09 per share a year ago.
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
11:00am, Wednesday, 08'th May 2024
SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, and Catalent Inc., the leader in enabling the development and supply of b
US FTC seeks more information on Novo Nordisk parent-Catalent deal
08:58am, Friday, 03'rd May 2024
The U.S. Federal Trade Commission has sought additional information about a $16.5 billion deal by Novo Nordisk's parent to buy manufacturing subcontractor Catalent.
TAK or CTLT: Which Is the Better Value Stock Right Now?
12:45pm, Thursday, 25'th Apr 2024
Investors with an interest in Medical - Drugs stocks have likely encountered both Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks presents investors with the better
Robbins LLP Reminds Stockholders it is Investigating the Acquisition of Catalent, Inc. (CTLT)
08:19pm, Wednesday, 17'th Apr 2024
SAN DIEGO--(BUSINESS WIRE)---- $CTLT #CTLT--Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT).
Here's Your Second Chance To Own 7 Leading Stocks Like Nvidia
08:00am, Wednesday, 17'th Apr 2024
Tired of listening to your neighbors bragging about all their winning S&P 500 stocks. You just got another shot at some.
Novo Nordisk parent refiles US application on Catalent deal
06:31am, Monday, 08'th Apr 2024
The parent of Wegovy producer Novo Nordisk has refiled an application to the U.S. Federal Trade Commission (FTC) for approval of a $16.5 billion deal to buy manufacturing subcontractor Catalent , a sp
Invenra Inc. Announces a Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs
01:54pm, Tuesday, 02'nd Apr 2024
MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global Contract Development and
International Companies Drive Diabesity Innovation
09:59am, Friday, 29'th Mar 2024
International Companies Drive Diabesity Innovation
Novo Owner's CEO on Obesity Sales Boom, Catalent Deal
06:25am, Tuesday, 12'th Mar 2024
Novo Holdings CEO Kasim Kutay discusses the surge in income from obesity drug sales and offers an update on the Catalent deal and insight on the company's deal strategy.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT
08:22pm, Monday, 11'th Mar 2024
NEW YORK , March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. ("Catalent" or the "Company") (NYSE: CTLT). Such investors are advised to c
Novo Nordisk expects Catalent deal to close later this year
10:31am, Thursday, 07'th Mar 2024
Novo Nordisk expects to close its acquisition of Catalent later this year, its chief financial officer said during the company's capital markets day on Thursday, adding that Novo's gross margin is see
Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment
08:00am, Thursday, 07'th Mar 2024
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, has today published its fiscal 2023 Corpora
